Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy
Authors:
Open Access
- 30 April 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1589243
Abstract
Laryngeal squamous cell carcinoma (LSCC) is a prevalent malignancy with high mortality and recurrence rates, necessitating novel therapeutic strategies. Recent research highlights the pivotal role of metabolic reprogramming and immune microenvironment alterations in LSCC pathogenesis, providing promising avenues for targeted therapy. This review summarizes the metabolic characteristics of LSCC, including glycolysis, lipid metabolism, and amino acid biosynthesis, and their implications for tumor progression and therapeutic resistance. Additionally, this review further describes the tumor microenvironment’s immunosuppressive landscape, including immune checkpoint regulation, tumor-associated macrophages, and T-cell dysfunction. The integration of metabolic and immune-targeted strategies represents a promising frontier in LSCC treatment, warranting further investigation.Keywords
This publication has 131 references indexed in Scilit:
- Knockdown of integrin β1 inhibits proliferation and promotes apoptosis in bladder cancer cellsBioFactors, 2024
- Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinomaCancer Immunology, Immunotherapy, 2024
- KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathwayCellular and Molecular Life Sciences, 2024
- Advances in HPV‐associated tumor management: Therapeutic strategies and emerging insightsJournal of Medical Virology, 2023
- Prognostic significance of tumor budding, tumor‐stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomasHead & Neck, 2019
- Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosisCancer Immunology, Immunotherapy, 2018
- Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and HypopharynxJAMA Otolaryngology–Head & Neck Surgery, 2016
- Cancer stem cells in laryngeal cancer: what we knowEuropean Archives of Oto-Rhino-Laryngology, 2015
- Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III–IV unresectable head and neck cancerStrahlentherapie und Onkologie, 2015
- Reexamining the treatment of advanced laryngeal cancerHead & Neck, 2009